A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans.

IF 4.7 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2019-01-01 DOI:10.1177/1753944719840192

Frank Tillman, Jennifer Kim, Tanya Makhlouf, Leah Osae

{"title":"A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans.","authors":"Frank Tillman, Jennifer Kim, Tanya Makhlouf, Leah Osae","doi":"10.1177/1753944719840192","DOIUrl":null,"url":null,"abstract":"Background: Our aim was to review the published literature evaluating treatment approaches for chronic heart failure (HF), notably as it relates to African American patients.Method: We undertook a comprehensive database search (1986-2017) of PubMed, EMBASE, and Ovid/MEDLINE utilizing terms 'African American', 'black', 'chronic heart failure', 'heart failure', 'medication', 'chronic therapy', and 'clinical trials'. Additional notable studies were obtained from ClinicalTrials.gov . Studies published in English that examine treatment modalities of chronic HF in African American and non-African American patients were included.Results: Examples of current gaps worthy of investigation include whether to maximize thiazides and calcium-channel blockers prior to adding renin-angiotensin system (RAS) inhibitors or beta blockers in HF with preserved ejection fraction; whether hydralazine/isosorbide dinitrate (ISDN) should be initiated during earlier HF stages; whether to prioritize hydralazine/ISDN over other agents such as RAS inhibitors; varying response of African Americans to different agents within drug classes; and the role of mineralocorticoid receptor antagonists.Conclusion: Further studies are needed in order for consensus guidelines to clarify how best to treat this population.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"1753944719840192"},"PeriodicalIF":4.7000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1753944719840192","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1753944719840192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 10

Abstract

Background: Our aim was to review the published literature evaluating treatment approaches for chronic heart failure (HF), notably as it relates to African American patients.

Method: We undertook a comprehensive database search (1986-2017) of PubMed, EMBASE, and Ovid/MEDLINE utilizing terms 'African American', 'black', 'chronic heart failure', 'heart failure', 'medication', 'chronic therapy', and 'clinical trials'. Additional notable studies were obtained from ClinicalTrials.gov . Studies published in English that examine treatment modalities of chronic HF in African American and non-African American patients were included.

Results: Examples of current gaps worthy of investigation include whether to maximize thiazides and calcium-channel blockers prior to adding renin-angiotensin system (RAS) inhibitors or beta blockers in HF with preserved ejection fraction; whether hydralazine/isosorbide dinitrate (ISDN) should be initiated during earlier HF stages; whether to prioritize hydralazine/ISDN over other agents such as RAS inhibitors; varying response of African Americans to different agents within drug classes; and the role of mineralocorticoid receptor antagonists.

Conclusion: Further studies are needed in order for consensus guidelines to clarify how best to treat this population.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非裔美国人慢性心力衰竭药物治疗方法综述。

背景：我们的目的是回顾已发表的评估慢性心力衰竭（HF）治疗方法的文献，尤其是与非裔美国人患者有关的文献。方法：我们对PubMed、EMBASE和Ovid/MEDLINE进行了全面的数据库搜索（1986-2017），使用术语“非裔美国人”、“黑人”、“慢性心力衰竭”、“心力衰竭”、《药物》、“慢性治疗”和“临床试验”。其他值得注意的研究来自ClinicalTrials.gov。以英语发表的研究检查了非裔美国人和非裔美国人患者的慢性HF治疗模式。结果：目前值得研究的差距包括，在射血分数保持的HF中，在添加肾素-血管紧张素系统（RAS）抑制剂或β受体阻滞剂之前，是否最大限度地增加噻嗪类药物和钙通道阻滞剂；肼嗪/二硝酸异山梨醇酯（ISDN）是否应在HF早期阶段启动；是否将肼嗪/ISDN优先于RAS抑制剂等其他制剂；非裔美国人对不同药物类别的不同制剂的不同反应；以及盐皮质激素受体拮抗剂的作用。结论：需要进一步的研究，以达成共识，明确如何最好地治疗这一人群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.